surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SURMOUNT-1: Tirzepatide Provides Significant, Sustained
Pay in 4 interest-free payments of $6.95 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SURMOUNT-1: Tirzepatide Provides Significant, Sustained](https://cdn.sanity.io/images/0vv8moc6/hcplive/2d6bf11cb5efe18f89bb0ef82348ac86e1637d77-2979x1675.jpg)
![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SURMOUNT-1: Tirzepatide Provides Significant, Sustained](https://www.thelancet.com/cms/10.1016/S0140-6736(23)01200-X/asset/1ec2c191-5a64-4856-842f-bfa65a8fabc6/main.assets/gr2.jpg)
![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SURMOUNT-1: Tirzepatide Provides Significant, Sustained](https://images.ctfassets.net/tkom1vk0n4w2/1taLAYCzYc5US0KeHbgqjI/8a15a9a7822c259c24f8b7646cd390ce/GettyImages-2170862186_1__2_.webp)





















